- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03291613
Gaming Technology to Engage Adolescent Sickle Cell Patients in Pain Management
14. januar 2019 opdateret af: Klein Buendel, Inc.
PINPOINT: Gaming Technology to Engage Adolescent Sickle Cell Patients in Precision Pain Management
Sickle cell disease (SCD) is a common genetic disorder characterized by episodes of pain, yet assessments to identify type, intensity, frequency, and phase of pain among SCD adolescents is lacking.
Research shows that interactive gaming technology can enhance adolescents' learning, and can be especially effective in delivering health-related messages and tools to improve their self-care.
Pinpoint is an interactive gaming tablet app that will be developed with the significant input of clinical experts to assist SCD teens with better identification and self-report of their pain.
Studieoversigt
Detaljeret beskrivelse
Sickle cell disease (SCD) is the most common inherited blood disorder in the U.S. and disproportionately affects African Americans and Hispanics.
Approximately, 1,000 U.S. children are born with SCD annually.
SCD results from abnormal hemoglobin and causes red blood cells (RBCs) to become misshaped ("sickle-shaped").
Sickled cells can block the flow of blood in small arteries causing tissue and organ damage and other life-threatening comorbidities.
SCD complications can be serious and have a significant impact upon well-being and quality of life.
Pain is the hallmark symptom associated with SCD, and is the most common clinical problem seen in children and the number one cause of SCD-related hospital admissions.
If left untreated, these painful episodes can result in morbidity and mortality.
Accurate assessment of pain specifiers (type, frequency, and intensity of pain) can help with ameliorating pain quickly and effectively.
Despite children being accurate self-reporters of their pain, strategies which are effective and engaging to assist with pain identification are lacking.
Reducing barriers to collection and promoting the value of accurate SCD pain assessment is a need in pediatric medicine.
Pinpoint will be an innovative interactive assessment tool that engages patients while allowing physicians to collect important health data.
This project will test the feasibility of applying gamification principles to develop a tablet application ("app") for 13-17 year olds with SCD.
Specifically, this Phase I SBIR project will (1) develop a Pain Assessment Tool (PAT) to describe and categorize specific types of pain experienced by adolescents with SCD; and (2) create an app ("Pinpoint"), that will translate the PAT into gamified technology.
The goal of Pinpoint is to engage adolescent patients and improve pain specification by developing a game-based pain assessment tool delivered via a tablet app to engage adolescent SCD patients, improve their pain specification self-report, and improve pain management by clinicians.
The PAT will be developed using expert guidance from preeminent SCD clinicians.
User-centered Design theory will be applied in the development of the app and will be guided by iterative cognitive interviews and focus groups with members of the target population, SCD teens.
The project specific aims are to (1) develop the PAT using guidance from an Expert Advisory Board (EAB) of SCD clinicians; (2) conduct a series of cognitive interviews with adolescent SCD patients to guide and refine PAT development; (3) conduct iterative focus groups with adolescent SCD patients to guide and refine user interface design of the Pinpoint app; (4) program a functional Pinpoint prototype; and (5) conduct usability testing of the prototype with 13-17 year old SCD patients to assess functionality, navigation, and satisfaction.
This project is innovative and timely.
Pinpoint will be the first tablet app to identify and translate specific pain types for SCD into a gamified app using applied gamification principles.
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
13
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Colorado
-
Golden, Colorado, Forenede Stater, 80401
- Klein Buendel, Inc.
-
-
Indiana
-
Munster, Indiana, Forenede Stater, 463213963
- Hilton Publishing Company
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
13 år og ældre (Barn, Voksen, Ældre voksen)
Tager imod sunde frivillige
Ja
Køn, der er berettiget til at studere
Alle
Beskrivelse
Phone Interview, Focus Group, and Usability Inclusion Criteria:
- Be 13-17 years of age
- Be diagnosed with Sickle Cell Disease
- Able to read and speak English
- Able to assent to participate
Phone Interview, Focus Group, and Usability Exclusion Criteria:
- Not 13-17 years of age
- Not diagnosed with Sickle Cell Disease
- Unable to read and speak English
- Unable to assent to participate
Healthcare Provider Interview Inclusion Criteria:
- Be a healthcare provider to teens with sickle cell disease
- Be 18 years of age or older
- Able to read and speak English
- Able to consent to participate
Healthcare Provider Interview Exclusion Criteria:
- Not a healthcare provider to teens with sickle cell disease
- Not 18 years of age or older
- Unable to read and speak English
- Unable to consent to participate
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Støttende pleje
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Pinpoint App
Tablet application.
|
Tablet app with pain assessment and communication education, and pain assessment tool.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
System Usability Questionnaire
Tidsramme: After 1-hour usability session
|
Ten likert-type questions assessing user-friendliness of technology.
Each question has five answer options that range from "Strongly Agree" to "Strongly Disagree".
Scores range from 0-100.
A score of 68 or above is considered above average.
All scores averaged.
|
After 1-hour usability session
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Generelle publikationer
- Schnog JB, Duits AJ, Muskiet FA, ten Cate H, Rojer RA, Brandjes DP. Sickle cell disease; a general overview. Neth J Med. 2004 Nov;62(10):364-74.
- Dampier C, Lieff S, LeBeau P, Rhee S, McMurray M, Rogers Z, Smith-Whitley K, Wang W; Comprehensive Sickle Cell Centers (CSCC) Clinical Trial Consortium (CTC). Health-related quality of life in children with sickle cell disease: a report from the Comprehensive Sickle Cell Centers Clinical Trial Consortium. Pediatr Blood Cancer. 2010 Sep;55(3):485-94. doi: 10.1002/pbc.22497.
- Brawley OW, Cornelius LJ, Edwards LR, Gamble VN, Green BL, Inturrisi C, James AH, Laraque D, Mendez M, Montoya CJ, Pollock BH, Robinson L, Scholnik AP, Schori M. National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. Ann Intern Med. 2008 Jun 17;148(12):932-8. doi: 10.7326/0003-4819-148-12-200806170-00220. Epub 2008 May 5. No abstract available.
- Cope A, Darbyshire PJ. Sickle cell disease, update on management. Paediatrics and Child Health. 2013;23(11):480-485.
- Mukerji I. About sickle cell disease.Sicklecellinfo.net Web site. Available at: http://www.sicklecellinfo.net/index.htm. Published 2004. Updated March 5, 2004. Accessed March 5, 2015.
- Bhagat VM, Baviskar SR, Mudey AB, Goyal RC. Poor health related quality of life among patients of sickle cell disease. Indian J Palliat Care. 2014 May;20(2):107-11. doi: 10.4103/0973-1075.132622.
- Stinson J, Naser B. Pain management in children with sickle cell disease. Paediatr Drugs. 2003;5(4):229-41. doi: 10.2165/00128072-200305040-00003.
- Ameringer S, Elswick RK Jr, Smith W. Fatigue in adolescents and young adults with sickle cell disease: biological and behavioral correlates and health-related quality of life. J Pediatr Oncol Nurs. 2014 Jan-Feb;31(1):6-17. doi: 10.1177/1043454213514632. Epub 2013 Dec 30.
- Dampier C, Ely B, Brodecki D, O'Neal P. Characteristics of pain managed at home in children and adolescents with sickle cell disease by using diary self-reports. J Pain. 2002 Dec;3(6):461-70. doi: 10.1054/jpai.2002.128064.
- Schatz J, Schlenz AM, McClellan CB, Puffer ES, Hardy S, Pfeiffer M, Roberts CW. Changes in coping, pain, and activity after cognitive-behavioral training: a randomized clinical trial for pediatric sickle cell disease using smartphones. Clin J Pain. 2015 Jun;31(6):536-47. doi: 10.1097/AJP.0000000000000183.
- Crandall M, Savedra M. Multidimensional assessment using the adolescent pediatric pain tool: a case report. J Spec Pediatr Nurs. 2005 Jul-Sep;10(3):115-23. doi: 10.1111/j.1744-6155.2005.00023.x.
- Franck LS, Treadwell M, Jacob E, Vichinsky E. Assessment of sickle cell pain in children and young adults using the adolescent pediatric pain tool. J Pain Symptom Manage. 2002 Feb;23(2):114-20. doi: 10.1016/s0885-3924(01)00407-9.
- Lopez G, Liles DK, Knupp CL. Edmonton Symptom Assessment System for outpatient symptom monitoring of sickle cell disease. South Med J. 2014 Dec;107(12):768-72. doi: 10.14423/SMJ.0000000000000209.
- Panepinto JA, O'Mahar KM, DeBaun MR, Loberiza FR, Scott JP. Health-related quality of life in children with sickle cell disease: child and parent perception. Br J Haematol. 2005 Aug;130(3):437-44. doi: 10.1111/j.1365-2141.2005.05622.x.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
15. januar 2017
Primær færdiggørelse (Faktiske)
30. september 2017
Studieafslutning (Faktiske)
30. september 2017
Datoer for studieregistrering
Først indsendt
20. september 2017
Først indsendt, der opfyldte QC-kriterier
20. september 2017
Først opslået (Faktiske)
25. september 2017
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
6. februar 2019
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
14. januar 2019
Sidst verificeret
1. januar 2019
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 1R43MD010746-01 (U.S. NIH-bevilling/kontrakt)
- 0308 (Klein Buendel, Inc.)
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Seglcellesygdom
-
Universitaire Ziekenhuizen KU LeuvenAktiv, ikke rekrutterendeLymfom | Hodgkin lymfom | Non-Hodgkin lymfom (follikulært, diffust B-cel lymfom, PTLD og Mantle Cel lymfom)Belgien
-
University of BolognaNovartisUkendtMyeloproliferative lidelser | Hypereosinofilt syndrom | Kronisk eosinofil leukæmi (CEL)Italien
-
AHS Cancer Control AlbertaCross Cancer InstituteAfsluttetOmfattende Stage Small Cel Lung CancerCanada
-
Novartis PharmaceuticalsAfsluttetKronisk myeloid leukæmi (CML) | Philadelphia kromosom positiv akut lymfoblastisk leukæmi (Ph+ ALL) | Andre Glivec/Gleevec-indicerede hæmatologiske lidelser (HES, CEL, MDS/MPN)Den Russiske Føderation
Kliniske forsøg med Pinpoint App
-
Klein Buendel, Inc.National Institute on Minority Health and Health Disparities (NIMHD); Hilton...AfsluttetSeglcellesygdom | Seglcelleanæmi hos børn | Seglcelle-thalassæmi | Seglcelle SC sygdomForenede Stater
-
Nirav Amin, MDTrukket tilbageRivning af rotatormanchetForenede Stater
-
University of California, Los AngelesNovadaq Technologies ULC, now a part of StrykerAfsluttet
-
Novadaq Technologies ULC, now a part of StrykerAfsluttetLivmoderhalskræft | Endometriecancer | LivmoderkræftForenede Stater, Canada, Puerto Rico
-
Stryker OrthopaedicsTrukket tilbageLaparoskopisk kolecystektomiKina
-
Rutgers, The State University of New JerseyPfizer; American Cancer Society, Inc.AfsluttetImmunterapi | Kliniske forsøgForenede Stater
-
University of FloridaSociety of University SurgeonsAfsluttetHepatocellulært karcinom | Kolecystitis | LevermetastaserForenede Stater
-
Novadaq Technologies ULC, now a part of StrykerAfsluttetEndetarmskræft | Rectosigmoid kræftForenede Stater
-
Novadaq Technologies ULC, now a part of StrykerAfsluttetEndetarmskræft | Crohns sygdom | Divertikulit | Tyktarmskræft | Polyp | ProcidentiaForenede Stater
-
St. Justine's HospitalAfsluttetTrauma | Nekrotiserende enterocolitis | Intestinal obstruktion | Gastroschisis | Intussusception | Intestinal atresi | Hirschsprung sygdom | Fængslet brok | Malrotation | Volvulus | Meconium Ileus | Intestinal perforeringCanada